Omeprazol Polpharma (Omeprazole Sodium)

Omeprazole belongs to the proton pump inhibitor class. It irreversibly inhibits the H+/K+ ATPase enzyme, also known as the gastric proton pump, located on the secretory surface of parietal cells. This inhibition blocks the final step of acid production, leading to a sustained increase in gastric pH and reduced acid‑related damage.

The dosage of Omeprazol Polpharma is determined by the prescribing healthcare professional based on the specific indication, severity of the condition, patient weight, renal and hepatic function, and other clinical factors. The prescriber will set the appropriate dose and infusion rate for each individual patient.

Safety data for omeprazole in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate each case individually and discuss potential risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if required), and necessary import documentation.

Omeprazol Polpharma, as an intravenous proton pump inhibitor, offers rapid and potent suppression of gastric acid compared with oral PPIs or H2‑receptor antagonists. Its IV route is advantageous in patients who cannot take oral medications, have severe ulcer disease, or require immediate acid control, whereas oral agents are generally used for maintenance therapy.

Omeprazol Polpharma should be stored at 2‑8 °C in a refrigerator. Keep the solution in its original container, protect it from light, and avoid freezing or shaking. Do not use the product if it appears discolored or if the storage temperature has been exceeded.

The product is supplied as an intravenous solution and is administered by slow infusion into a vein, typically through a peripheral or central line. Administration should be performed by qualified healthcare personnel in a clinical setting, following the prescribing information for infusion rate and duration.

Serious adverse reactions, although rare, include Clostridioides difficile‑associated diarrhea, severe allergic reactions such as anaphylaxis, hepatic dysfunction, neutropenia, thrombocytopenia, and interstitial nephritis. Patients should be monitored for signs of infection, liver injury, blood count changes, and allergic responses during therapy.

Omeprazol Polpharma is contraindicated in patients with known hypersensitivity to omeprazole or any component of the formulation. Caution is advised for individuals with severe hepatic impairment, those receiving clopidogrel, and patients with a history of allergic reactions to proton pump inhibitors. The prescriber should assess suitability before initiating therapy.